glp 1 agonist and alcohol use disorder GLP-1 RAs may reduce alcohol-related hospitalization risk How GLP-1 Drugs Are Impacting

J.EricksonK

WADA Status: Melanotan II: Prohibited (melanocortin peptide) PT-141/Bremelanotide: Prohibited (melanocortin agonist) Kisspeptin: Not explicitly listed, but GnRH modulators are prohibited Athletes subject to anti-doping testing should avoid all these compounds

Food and Drug Administration (FDA) DailyMed Label: Bacteriostatic Water for Injection (Provides official labeling, storage instructions, and preservative information) United States Pharmacopeia (USP) USPNF General Chapters & Monographs (Defines standards for sterile water for injection and pharmaceutical quality requirements) World Health Organization (WHO) WHO Good Storage and Distribution Practices (Guidelines for temperature control, sterility, and pharmaceutical handling) American Society of Health-System Pharmacists (ASHP) (Clinical guidance on sterile product handling and multi-dose vial use) FDA Guidance on Sterile Drug Products (Aseptic handling, contamination risk, and storage principles)

Faster escalation (8-week to 2.4mg) Accelerated titration: Weeks 1-2: 0.6mg weekly Weeks 3-4: 1.2mg weekly Weeks 5-6: 1.8mg weekly Week 7+: 2.4mg weekly Who can attempt: No significant nausea on GLP-1s previously Generally strong GI tolerance Motivated for rapid weight loss Willing to accept higher side effect risk Can reduce dose if needed Expected experience: More pronounced nausea (weeks 3-5 especially) Faster adaptation curve Quicker weight loss onset Reaches maximum efficacy 4+ weeks sooner Success factors: Aggressive nausea management from start Ginger, B6, anti-nausea meds ready Small meal prep planned Ready to slow down if needed Higher maintenance doses (3.0-4.5mg) Rationale: Trials showed 3.0mg and 4.5mg produce slightly more weight loss Some individuals tolerate well Investigational approach 3.0mg weekly: ~11% average weight loss Moderate increase in side effects Reasonable middle ground Some find optimal here 4.5mg weekly: ~12% average weight loss (maximum) Significantly worse nausea/vomiting High dropout rate Not recommended routinely Only for exceptional tolerators Titration to higher doses: Reach 2.4mg first (standard titration) Stable at 2.4mg for 4-8 weeks Increase to 3.0mg if tolerating perfectly Consider 4.5mg only if 3.0mg easy Risk-benefit analysis: 3.0mg: May be worth it for some (1% extra loss) 4.5mg: Usually not worth it (2% extra loss, major side effects) Cost increases proportionally Individual decision Combination with other peptides for synergy Cagrilintide + Semaglutide (CagriSema): Most studied, proven synergy Both at 2.4mg weekly 15-25% total weight loss See detailed combination protocols below Cagrilintide + CJC-1295/Ipamorelin: Cagrilintide: 2.4mg weekly (fat loss) CJC-1295: 200-300mcg 5x weekly (muscle preservation) Ipamorelin: 200-300mcg 5x weekly (body composition) Preserves muscle during aggressive weight loss Better body composition outcomes Cagrilintide + BPC-157: Cagrilintide: 2.4mg weekly (weight loss) BPC-157: 250-500mcg twice daily (gut health) BPC-157 may help with GI side effects Supports gut during weight loss Complementary mechanisms See our peptide stacks guide , peptide stack calculator , CJC-1295 dosage calculator , Ipamorelin benefits , BPC-157 guide , and BPC-157 dosage calculator